|
SW620 [SW-620]
|
|
A Leibovitz
|
Biosafety Level:
|
1
|
|
frozen
|
|
See Propagation
|
|
adherent
|
|
Homo sapiens (human)
|
|
epithelial
|
|
Organ: colon
Tumor Stage: Dukes' type C
Disease: colorectal adenocarcinoma
Derived from metastatic site: lymph node
|
|
carcinoembryonic antigen (CEA) 0.15 ng/10 exp6 cells/10 days; transforming growth factor alpha; keratin; matrilysin
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
transfection host (Roche FuGENE® Transfection Reagents)
|
|
Yes
|
|
myc +; myb + ; ras +; fos +; sis +; p53 +; abl -; ros -; src -
|
|
blood type A; Rh+
|
|
Amelogenin: X
CSF1PO: 13,14
D13S317: 12
D16S539: 9,13
D5S818: 13
D7S820: 8,9
THO1: 8
TPOX: 11
vWA: 16
|
|
modal number = 50; range = 45 to 53, The stemline chromosome number is hyperdiploid with the 2S component occurring at 12% and 11 marker chromosomes were common to S metaphases. One of the 11 markers [7 (7p; 11p)] was disomic., M1 was probably an HSR but the origin of the chromosome could not be identified.
|
|
ES-D, 1
G6PD, B
PEP-D, 1
PGD, A
PGM1, 2
PGM3, 1
|
|
51 years
|
|
male
|
|
Caucasian
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:10 is recommended
Medium Renewal: 2 to 3 times per week
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
|
|
culture medium 95%; DMSO, 5%
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2008
recommended serum:ATCC 30-2020
derived from same individual:ATCC CCL-228
|
|
22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
22545: Lelbovitz A, et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J. Natl. Cancer Inst. 63: 635-645, 1979. PubMed: 288927
22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874
23025: Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501
23322: Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228
49853: Witty JP, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54: 4805-4812, 1994. PubMed: 8062282
56129: Gagos S, et al. Chromosomal markers associated with metastasis in two colon cancer cell lines established from the same patient. Anticancer Res. 15: 369-378, 1995. PubMed: 7763008
56130: Melcher R, et al. Spectral karyotyping of the human colon cancer cell lines SW480 and SW620. Cytogenet. Cell Genet. 88: 145-152, 2000. PubMed: 10773689
|